Intercept Pharma (ICPT) Misses Q4 EPS by $1.10, Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update
February 23, 2017 7:05 AM ESTNet Ocaliva® (obeticholic acid or OCA) 4Q16 sales of $13.4 million, full year 2016 net sales of $18.2 millionEnrollment of Phase 3 REGENERATE interim analysis cohort anticipated completion by mid-2017Data expected from two Phase 2 trials for OCA in 2017Planned initiation of Phase 2 trial of INT-767 in 2017
Conference call scheduled... More
